阿片类使用障碍治疗中回归使用的个体化风险预测
本研究基于3项多中心随机临床试验的2199例接受美沙酮、丁丙诺啡或缓释纳曲酮治疗的阿片类使用障碍患者数据,开发个体化预测工具。仅用治疗入口4个预测因子AUROC为0.67,加入前3周尿药筛查结果后AUROC提升至0.82。简化评分显示治疗初始3周内每周尿阿片阴性者回归使用风险13%,而3周均阳性或缺失者风险达85%。
要点
- 基于治疗入口4个预测因子的模型AUROC为0.67,加入前3周尿药筛查后提升至0.82。
- 简化CTN-0094评分可区分风险:3周尿阿片阴性者回归风险13%,阳性或缺失者85%。
- 预防回归规律使用的干预应聚焦治疗开始后前3周这一关键窗口期。
核心结论
- 该预测模型可能成为治疗第3周时通用的阿片类回归使用风险测量工具。
研究设计与样本
- 决策分析模型,使用2019年6月1日至2022年10月1日 harmonized 的个体数据,来自2006至2016年间美国国家药物滥用研究所临床试验网络(CTN)的3项多中心、实用型、随机临床试验,疗程至少12周。
- 3项试验覆盖联邦许可治疗点、医生诊所和住院治疗机构等多种治疗场景,纳入18岁以上成人,排除标准少,仅排除重大医学和不稳定精神共病。
- 总样本2199例,平均(SD)年龄35.3(10.7)岁,女性728例(33.1%),男性1471例(66.9%)。
- 所有参与者接受美沙酮、丁丙诺啡或缓释纳曲酮之一治疗。
主要发现
- 基于治疗入口4个预测因子(海洛因使用天数、吗啡和可卡因阳性尿药筛查结果、过去30天海洛因注射)的最终模型AUROC为0.67(95% CI,0.62-0.71)。
- 加入治疗前3周尿药筛查结果后模型性能提升,AUROC为0.82(95% CI,0.78-0.85)。
- 简化评分(CTN-0094 OUD回归使用风险评分)提供良好的临床风险分层:治疗开始后3周内每周尿阿片阴性者回归使用风险为13%,而3周尿阿片阳性或缺失者风险为85%(AUROC,0.80;95% CI,0.76-0.84)。
关键数值与推荐
- 回归使用定义为治疗第12周前连续4周尿药筛查结果缺失或非处方阿片类阳性。
- 简化评分基于治疗开始后前3周每周尿阿片筛查结果进行风险分层。
临床怎么用
- 临床可在治疗第3周使用简化评分识别高回归风险患者,并针对前3周这一关键早期治疗期加强预防干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: No existing model allows clinicians to predict whether patients might return to opioid use in the early stages of treatment for opioid use disorder. OBJECTIVE: To develop an individual-level prediction tool for risk of return to use in opioid use disorder. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model used predictive modeling with individual-level data harmonized in June 1, 2019, to October 1, 2022, from 3 multicenter, pragmatic, randomized clinical trials of at least 12 weeks' duration within the National Institute on Drug Abuse Clinical Trials Network (CTN) performed between 2006 and 2016. The clinical trials covered a variety of treatment settings, including federally licensed treatment sites, physician practices, and inpatient treatment facilities. All 3 trials enrolled adult participants older than 18 years, with broad pragmatic inclusion and few exclusion criteria except for major medical and unstable psychiatric comorbidities. INTERVENTION: All participants received 1 of 3 medications for opioid use disorder: methadone, buprenorphine, or extended-release naltrexone. MAIN OUTCOMES AND MEASURES: Predictive models were developed for return to use, which was defined as 4 consecutive weeks of urine drug screen (UDS) results either missing or positive for nonprescribed opioids by week 12 of treatment. RESULTS: The overall sample included 2199 trial participants (mean [SD] age, 35.3 [10.7] years; 728 women [33.1%] and 1471 men [66.9%]). The final model based on 4 predictors at treatment entry (heroin use days, morphine- and cocaine-positive UDS results, and heroin injection in the past 30 days) yielded an area under the receiver operating characteristic curve (AUROC) of 0.67 (95% CI, 0.62-0.71). Adding UDS in the first 3 treatment weeks improved model performance (AUROC, 0.82; 95% CI, 0.78-0.85). A simplified score (CTN-0094 OUD Return-to-Use Risk Score) provided good clinical risk stratification wherein patients with weekly opioid-negative UDS results in the 3 weeks after treatment initiation had a 13% risk of return to use compared with 85% for those with 3 weeks of opioid-positive or missing UDS results (AUROC, 0.80; 95% CI, 0.76-0.84). CONCLUSIONS AND RELEVANCE: The prediction model described in this study may be a universal risk measure for return to opioid use by treatment week 3. Interventions to prevent return to regular use should focus on this critical early treatment period.
引用
- Luo SX, Feaster DJ, Liu Y, et al. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2024. PMID: 37792357. doi:10.1001/jamapsychiatry.2023.3596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。